Quartz Partners LLC Makes New Investment in Amneal Pharmaceuticals, Inc. $AMRX

Quartz Partners LLC acquired a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 447,200 shares of the company’s stock, valued at approximately $5,559,000. Amneal Pharmaceuticals comprises 2.1% of Quartz Partners LLC’s holdings, making the stock its 10th largest position.

Other hedge funds also recently modified their holdings of the company. Assenagon Asset Management S.A. increased its position in shares of Amneal Pharmaceuticals by 75.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 3,761,739 shares of the company’s stock valued at $47,398,000 after acquiring an additional 1,611,698 shares during the last quarter. Westshore Wealth LLC acquired a new position in Amneal Pharmaceuticals during the third quarter valued at approximately $13,833,000. Morgan Stanley grew its stake in Amneal Pharmaceuticals by 37.5% in the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock valued at $60,708,000 after purchasing an additional 1,315,018 shares in the last quarter. Penn Capital Management Company LLC bought a new position in Amneal Pharmaceuticals in the fourth quarter valued at approximately $12,655,000. Finally, Rubric Capital Management LP increased its position in shares of Amneal Pharmaceuticals by 9.1% during the 2nd quarter. Rubric Capital Management LP now owns 11,710,332 shares of the company’s stock worth $94,737,000 after purchasing an additional 974,355 shares during the last quarter. Institutional investors own 31.82% of the company’s stock.

Insiders Place Their Bets

In related news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the sale, the director owned 93,660 shares in the company, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 17.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. UBS Group upped their price objective on Amneal Pharmaceuticals from $19.00 to $23.00 and gave the stock a “buy” rating in a research note on Wednesday. Barclays raised their target price on shares of Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 20th. Zacks Research lowered shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, May 26th. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Sunday, July 12th. Five investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.60.

Amneal Pharmaceuticals Stock Up 4.9%

Shares of NASDAQ AMRX opened at $18.04 on Friday. The business’s 50 day moving average price is $14.95 and its two-hundred day moving average price is $13.86. The company has a market cap of $5.76 billion, a PE ratio of 47.47 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a twelve month low of $7.66 and a twelve month high of $18.08.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%.The company had revenue of $722.52 million during the quarter. As a group, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.